Currently Viewing:
Evidence-Based Oncology December 2015
Three Proposals to Reform the 340B Drug Discount Program
Rena M. Conti, PhD; Peter B. Bach, MD, MAPP; Michael Kolodziej, MD
"Financial Toxicity": A New Term, but Not a New Reality for Many Cancer Patients
Debra Madden
Is There a Mathematical Resolution to the Cost-Versus-Value Debate?
Bruce Feinberg, DO; Lincy S. Lal, PharmD, PhD; J. Michael Swint, PhD
Maximizing Value of Freestanding and Outpatient Hospital Setting in Cancer Care Delivery
Constantine Mantz, MD
Managing Costs and Enhancing the Value of Oncology Care
Surya Singh, MD; Christine Sawicki, RPh, MBA; Ken Vander Pyl; Alan Lotvin, MD
Eliminating a Barrier to Cancer Care through Universal Fair Access to Oral Chemotherapy Medications
Christopher Hansen
Currently Reading
Impact of Oral Parity: A Personal Story
Christopher Hansen
The Financial Impact of Cancer Care: Implications and Potential Solutions
Veena Shankaran, MD, MS
Patient Access to Oncology Care in ACA Exchange Plans
Caroline F. Pearson and Deirdre B. Parsons, MPP, MPH, MS
The Struggle Between Oncology Care Cost and Value
Joseph Alvarnas, MD
COA Payer Summit
Surabhi Dangi-Garimella, PhD
ACCC ICLIO meeting
Surabhi Dangi-Garimella, PhD
FDA Updates: Oncology
Surabhi Dangi-Garimella, PhD
Managed Care Updates: Oncology
Surabhi Dangi-Garimella, PhD

Impact of Oral Parity: A Personal Story

Christopher Hansen
Oral chemotherapy ensured improved quality of life for a young, stage 3 pancreatic cancer patient.
Alexander (Xan) Harwood-Karlik was 29 years old when he was diagnosed with stage 3 pancreatic cancer in November 2014. Living in Portland, Oregon, and working as a recruiter for a higher education company, he started to feel abdominal pain that would intensify each afternoon and evening. Initially he was diagnosed with pancreatitis, but given Xan’s active lifestyle and healthy diet, a persistent primary care doctor was not satisfied with that diagnosis. Further tests revealed a walnut-sized tumor on his pancreas— devastating news to learn that he had been diagnosed with one of the most aggressive types of cancer at such a young age.

After a very difficult couple of weeks, his family and his oncologist were able to figure out a treatment plan that started with intravenous (IV) chemotherapy administered continuously through a pump for 4 treatments of 55 hours each, over 8 weeks. The pump came with many side effects, including pain at the port site, inability to exercise, stress over protecting the pump line, and anxiety over hearing the sound of the medicine dripping into his system every 45 minutes.

When it came time to discuss the next phase of his treatment plan that would involve over 5 weeks of a combination of chemotherapy and radiation, Xan’s oncologist and the director of the clinical trial he had enrolled in fought hard to make sure Xan could get the oral equivalent of his chemotherapy, because it would immensely improve his quality of life. Oregon was the first state to pass a law requiring insurers cover oral chemotherapy drugs just as they would IV chemotherapies, so Xan received no push back from his insurance company when his doctors prescribed him the oral chemotherapy medication. Although the oral chemotherapy had some traditional effects of chemotherapy—namely nausea and fatigue—the ability to take this medication orally meant “a major improvement in my ability to move around and conduct my daily life,” said Xan.

Following surgery in May 2015 that removed a significant portion of the tumor and other cancerous tissue in his abdomen, doctors saw no trace of cancer. In November, a scan showed cancer in Xan’s liver. Doctors are working to again balance an aggressive cancer treatment plan with as little interruption as possible in Xan’s daily routine. EBO
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up

Sign In

Not a member? Sign up now!